Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment

Phase 3TerminatedNCT00417833

Asociación para Evitar la Ceguera en México

Overview

Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion received intravitreal bevacizumab (2.5mg/0.1cc). All patients underwent best corrected visual acuity, fluorescein angiography, optical coherent tomography and mf-ERG before and 1 month after treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Conditions

Diabetic Proliferative Retinopathy Vascular Vein Oclussion Choroidal Neovascularization

Interventions

Intravitreal BevacizumabDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Proliferative diabetic retinopathy, vascular vein oclussion, choroidal neovascularization * Multifocal electroretinogram before intravitreal bevacizumab and at 1,3, and 6 months after treatment * Completely studies Exclusion Criteria: Complications * Tractional Detachment * Endophthalmitis

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.